CareDx, Inc (NASDAQ:CDNA – Get Free Report) has earned an average recommendation of “Moderate Buy” from the five brokerages that are covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $16.50.
CDNA has been the topic of a number of research reports. The Goldman Sachs Group boosted their price objective on CareDx from $10.00 to $14.00 and gave the stock a “buy” rating in a research report on Monday, May 13th. Craig Hallum upped their price target on CareDx from $15.00 to $22.00 and gave the company a “buy” rating in a research report on Friday, May 17th. Stephens upped their price target on CareDx from $15.00 to $18.00 and gave the company an “overweight” rating in a research report on Monday, May 13th. Raymond James lowered CareDx from an “outperform” rating to a “market perform” rating in a research report on Monday, May 13th. Finally, StockNews.com downgraded CareDx from a “buy” rating to a “hold” rating in a research note on Wednesday.
Read Our Latest Report on CDNA
Institutional Trading of CareDx
CareDx Trading Up 0.6 %
NASDAQ:CDNA opened at $14.06 on Thursday. The stock has a market cap of $732.24 million, a P/E ratio of -4.11 and a beta of 1.77. The stock has a 50 day simple moving average of $12.45 and a 200 day simple moving average of $10.96. CareDx has a 1-year low of $4.80 and a 1-year high of $17.03.
CareDx (NASDAQ:CDNA – Get Free Report) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.18. CareDx had a negative return on equity of 55.08% and a negative net margin of 66.59%. The company had revenue of $72.05 million for the quarter, compared to analyst estimates of $63.63 million. As a group, sell-side analysts forecast that CareDx will post -1.49 EPS for the current year.
CareDx Company Profile
CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.
Featured Stories
- Five stocks we like better than CareDx
- The How And Why of Investing in Oil Stocks
- McDonald’s Stock: Balancing Value and Innovation
- Dividend Payout Ratio Calculator
- MarketBeat Week in Review – 6/17 – 6/21
- How to Calculate Options Profits
- Sarepta Therapeutics Stock Soars on FDA Approval
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.